The Aβ‐clearance protein transthyretin, like neprilysin, is epigenetically regulated by the amyloid precursor protein intracellular domain
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Proteolytic cleavage of the amyloid precursor protein (APP) by the successive actions of β‐ and γ‐secretases generates several biologically active metabolites including the amyloid β‐peptide (Aβ) and the APP intracellular domain (AICD). By analogy with the Notch signalling pathway, AICD has been proposed to play a role in transcriptional regulation. Among the cohort of genes regulated by AICD is the Aβ‐degrading enzyme neprilysin (NEP). AICD binds to the NEP promoter causing transcriptional activation by competitive replacement with histone deacetylases (HDAC s) leading to increased levels of NEP activity and hence increased Aβ clearance. We now show that the Aβ‐clearance protein transthyretin (TTR) is also epigenetically up‐regulated by AICD. Like NEP regulation, AICD derived specifically from the neuronal APP isoform, APP695, binds directly to the TTR promoter displacing HDAC 1 and HDAC 3. Cell treatment with the tyrosine kinase inhibitor Gleevec (imatinib) or with the alkalizing agent NH4 Cl causes an accumulation of ‘functional’ AICD capable of up‐regulating both TTR and NEP, leading to a reduction in total cellular Aβ levels. Pharmacological regulation of both NEP and TTR might represent a viable therapeutic target in Alzheimer's disease. image Amyloid precursor protein (APP) intracellular domain (AICD) regulates expression of the amyloid (Aβ)‐degrading enzyme neprilysin (NEP). The Aβ‐clearance protein transthyretin (TTR) is also epigenetically regulated by AICD, derived specifically from the neuronal APP 695 isoform. Cell treatment with agents up‐regulating ‘functional’ AICD increases production of TTR and NEP and reduces Aβ levels which might represent a viable therapeutic target in Alzheimer's disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline
Jonsson, T., Atwal, J. K., Steinberg, S., Snaedal, J., Jonsson, P. V., Bjornsson, S., Stefansson, H., Sulem, P., Gudbjartsson, D., Maloney, J., et al. (2012) · Nature · doi:10.1038/nature11283 · Cited by 1,738 · cited 1×
“Indeed, a very recent report identifying the first human mutation in APP (A673T) that protects against AD and age-related cognitive decline provides an independent proof of principle of the amyloid hypothesis (Jonsson et al. 2012).”
BackgroundThe amyloid hypothesis for Alzheimer’s disease: A critical reappraisal
Hardy, J. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06181.x · Cited by 814 · cited 1×
“Recent reappraisals of the amyloid hypothesis have, however, highlighted that APP metabolites in addition to Ab contribute to, or can protect against, AD pathogenesis and may provide new opportunities for therapeutic intervention (Hardy 2009; Pimplikar et al. 2010).”
BackgroundProteolytic Degradation of Amyloid -Protein
Saido, T., & Leissring, M. A. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006379 · Cited by 368
Zuccato, C., Belyaev, N., Conforti, P., Ooi, L., Tartari, M., Papadimou, E., MacDonald, M., Fossale, E., Zeitlin, S., Buckley, N., et al. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.4278-06.2007 · Cited by 288
Self-citation
Cited by
Role of Prenatal Hypoxia in Brain Development, Cognitive Functions, and Neurodegeneration
Nalivaeva, N. N., Turner, A. J., & Zhuravin, I. A. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00825 · Cited by 181
“, Gleevec and bexarotene) which are able to upregulate expression of neprilysin and other amyloid-clearing proteins, including a transport protein transthyretin and insulindegrading enzyme (Kerridge et al., 2014; Nalivaeva et al., 2016).”
BackgroundMethodSelf-citationYang, S.-S., Zhang, R., Wang, G., & Zhang, Y.-F. (2017) · Translational Neurodegeneration · doi:10.1186/s40035-017-0089-1 · Cited by 163
Critical review: involvement of endoplasmic reticulum stress in the aetiology of Alzheimer's disease
Hashimoto, S., & Saido, T. C. (2018) · Open Biology · doi:10.1098/rsob.180024 · Cited by 129
Bukhari, H., Glotzbach, A., Kolbe, K., Leonhardt, G., Loosse, C., & Müller, T. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2017.05.005 · Cited by 88
Metadata
- Authors
- Kerridge, C., Belyaev, N. D., Nalivaeva, N. N., & Turner, A. J.
- Venue
- Journal of Neurochemistry
- Publisher
- Wiley
- Published
- 2014-03-12
- Volume
- 130
- Issue
- 3
- Pages
- 419-431
- ISSN
- 0022-3042 (ISSN-L)
- 1471-4159
- OpenAlex
- W1973415774
- Cited by
- 80
- References
- 4
- FWCI
- 6.22
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.